Supplementary Figure 1 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial

PDF file - 13027K, Comparison of apparent avidities of NY-ESO-1-specific CD4+ T cells before and after vaccination. Apparent avidity (EC50) for recognition of the NY-ESO-1 assay OLP was determined for NY-ESO-1-specific CD4+ T cell lines before and after the vaccination. (A) Cohort 1 (OLP alone); (B) Cohort 2 (OLP in Montanide); and (C) Cohort 3 (OLP and poly-ICLC in Montanide).